Quick Answer
Monopar Therapeutics reported Total Revenue of $0.00 for fiscal year 2019.
Monopar Therapeutics — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$13.72M +12.0% |
-$15.59M -85.5% |
-$8.40M +20.1% |
-$10.52M -15.5% |
-$9.10M -44.4% |
-$6.30M -49.2% |
| Total Assets | $140.72M +133.4% |
$60.29M +720.8% |
$7.35M -44.5% |
$13.23M -35.5% |
$20.52M +21.7% |
$16.87M +26.3% |
| Cash and Equivalents | $61.83M +35.0% |
$45.82M +530.6% |
$7.27M -11.2% |
$8.19M -59.7% |
$20.30M +21.3% |
$16.74M +26.7% |
| Stockholders Equity | $137.83M +150.4% |
$55.04M +885.0% |
$5.59M -44.6% |
$10.09M -46.7% |
$18.94M +20.7% |
$15.69M +24.3% |
| R&D Expense | $9.90M -23.8% |
$13.01M +132.2% |
$5.60M -26.2% |
$7.59M +16.9% |
$6.49M +59.7% |
$4.07M +106.5% |
| Operating Income | -$16.70M -3.4% |
-$16.16M -83.0% |
-$8.83M +16.2% |
-$10.54M -15.4% |
-$9.13M -40.2% |
-$6.51M -50.5% |
| Shares Outstanding | 6.69M +9.7% |
6.10M +104.7% |
2.98M -77.0% |
12.95M +2.8% |
12.60M +10.0% |
11.45M +8.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2019 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$3.44M | -163.6% | -40.1% |
| Total Assets | September 30, 2025 | $144.20M | +2275.7% | +167.7% |
| Cash and Equivalents | September 30, 2025 | $127.68M | +2020.9% | +223.2% |
| Stockholders Equity | September 30, 2025 | $141.56M | +2761.6% | +171.2% |
| R&D Expense | September 30, 2025 | $2.59M | +163.1% | +49.7% |
| Operating Income | September 30, 2025 | -$4.09M | -159.9% | -26.6% |
| Shares Outstanding | September 30, 2025 | 6.66M | +89.0% | +8.7% |
- Monopar Therapeutics reported Total Revenue of $0.00 for fiscal year 2019.
- Monopar Therapeutics reported Net Income of -$13.72 million for fiscal year 2025.
- Monopar Therapeutics showed an increase of +12.0% in Net Income compared to the prior fiscal year.
- Monopar Therapeutics reported Total Assets of $140.72 million for fiscal year 2025.
- Monopar Therapeutics showed an increase of +133.4% in Total Assets compared to the prior fiscal year.
- Monopar Therapeutics reported Cash and Equivalents of $61.83 million for fiscal year 2025.
- Monopar Therapeutics showed an increase of +35.0% in Cash and Equivalents compared to the prior fiscal year.
- Monopar Therapeutics reported Stockholders Equity of $137.83 million for fiscal year 2025.
- Monopar Therapeutics showed an increase of +150.4% in Stockholders Equity compared to the prior fiscal year.
- Monopar Therapeutics reported R&D Expense of $9.90 million for fiscal year 2025.
- Monopar Therapeutics showed a decrease of -23.8% in R&D Expense compared to the prior fiscal year.
- Monopar Therapeutics reported Operating Income of -$16.70 million for fiscal year 2025.
- Monopar Therapeutics showed a decrease of -3.4% in Operating Income compared to the prior fiscal year.
- Monopar Therapeutics reported Shares Outstanding of 6.69 million shares for fiscal year 2025.
- Monopar Therapeutics showed an increase of +9.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: